How does febuxostat stop gout attacks?
Febuxostat blocks an enzyme called xanthine oxidase, which your body uses to make uric acid. By cutting uric acid production by 60–70%, it prevents uric acid crystals from forming in your joints and triggering gout pain [2].
In clinical trials, febuxostat 80 mg daily lowered uric acid to target levels (<6 mg/dL) in 60–70% of patients within 2–4 weeks—faster than allopurinol's 8–12 week timeline [2]. The 2016 EULAR gout guidelines recommend febuxostat as a first-line urate-lowering therapy for patients who cannot tolerate or do not respond to allopurinol [1].
Inside your body, febuxostat travels to your liver and kidneys, where it binds tightly to xanthine oxidase and shuts down the enzyme's ability to convert hypoxanthine and xanthine into uric acid. This selective inhibition means fewer uric acid crystals form in your bloodstream and joints, reducing gout flare frequency by 70–80% over 6 months [2].
In real-world practice, most patients need 2–4 weeks to feel relief because uric acid must drop below 6 mg/dL before existing joint crystals dissolve. During the first month, your doctor may prescribe a low-dose steroid or colchicine to prevent flares while febuxostat works [1].
Ask your doctor to check your uric acid level 2 weeks after starting febuxostat. If it's still above 6 mg/dL, your dose may need to increase to 120 mg daily (off-label, requires clinician approval).